Mike Page has more than 25 years’ experience in the pharmaceutical industry with over 20 years in regulatory affairs. At Alexion, Mike is responsible for the developing and executing regulatory strategy across the portfolio of development and approved products. Prior to joining Alexion, Mike was US Regulatory Lead for the oncology therapeutic area at Eisai and was also responsible for regulatory aspects of the company’s biologics subsidiary, Morphotek. Prior to joining Eisai, Mike was a regulatory affairs consultant at United BioSource Corporation before which was a Director of Regulatory Strategy and Registration at Pfizer, both in the United Kingdom and the United States. Focusing mainly on late stage development and product registration, Mike has global registration experience in various therapeutic areas including oncology, psychiatry, sexual health and addiction disorders.